GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » FCF Margin %

Albert Labs International (XCNQ:ABRT) FCF Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Albert Labs International's Free Cash Flow for the three months ended in Sep. 2023 was C$-0.01 Mil. Albert Labs International's Revenue for the three months ended in Sep. 2023 was C$0.00 Mil. Therefore, Albert Labs International's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Albert Labs International's current FCF Yield % is -132.53%.

The historical rank and industry rank for Albert Labs International's FCF Margin % or its related term are showing as below:


XCNQ:ABRT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -143.795
* Ranked among companies with meaningful FCF Margin % only.


Albert Labs International FCF Margin % Historical Data

The historical data trend for Albert Labs International's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International FCF Margin % Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
FCF Margin %
- -

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albert Labs International's FCF Margin %

For the Biotechnology subindustry, Albert Labs International's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albert Labs International's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albert Labs International's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Albert Labs International's FCF Margin % falls into.



Albert Labs International FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Albert Labs International's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-1.497/0
= %

Albert Labs International's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.01/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albert Labs International FCF Margin % Related Terms

Thank you for viewing the detailed overview of Albert Labs International's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International Headlines

No Headlines